Cjc 1295 With Dac For Sale
Sourcing high-purity CJC-1295 with DAC requires stringent analytical verification to ensure experimental accuracy in preclinical growth factor models. PX1 Research supplies reference-standard CJC-1295 with DAC manufactured in domestic GMP-compliant facilities and tested by independent ISO 17025 laboratories.
Quick answer
Sourcing high-purity CJC-1295 with DAC requires stringent analytical verification to ensure experimental accuracy in preclinical growth factor models. PX1 Research supplies reference-standard CJC-1295 with DAC manufactured in domestic GMP-compliant facilities and tested by independent ISO 17025 laboratories.
Key takeaways
- When procurement officers and laboratory investigators evaluate candidates when looking for [cjc 1295 with dac for sale](/product/cjc-1295-with-dac), chemical identity, purity, and batch uniformity are the primary parameters required to yield reproducible data.
- Understanding the biochemistry of [CJC-1295](/research-peptides/cjc-1295-no-dac) with DAC requires examining both its primary amino acid sequence and the reactive functional group attached to its C-terminus.
- In animal literature, the pharmacokinetic profile of [CJC-1295](/research-peptides/cjc-1295-no-dac) with DAC contrasts sharply with non-conjugated secretagogues.
- When designing preclinical experiments, investigators must select the precise GHRH analog that matches their pharmacokinetic requirements.
Analytical Grade CJC-1295 With DAC for Research Applications
When procurement officers and laboratory investigators evaluate candidates when looking for cjc 1295 with dac for sale, chemical identity, purity, and batch uniformity are the primary parameters required to yield reproducible data. CJC-1295 with Drug Affinity Complex (DAC) is a synthetic 30-amino acid tetrasubstituted peptide analog of human growth hormone-releasing hormone (GHRH). It is specifically engineered to extend terminal elimination half-life through covalent bioconjugation in biological fluids.
In contrast to native GHRH(1-29), which exhibits a plasma half-life of less than twelve minutes in mammalian models due to rapid enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV), CJC-1295 with DAC incorporates structural modifications that resist metabolic cleavage. Investigators utilizing this research compound in preclinical protocols evaluate its sustained bioactivity on somatotrophic signaling pathways, pituitary secretion dynamics, and downstream insulin-like growth factor 1 (IGF-1) transcription.
PX1 Research provides fully characterized, reference-grade peptides synthesized under strict Quality Assurance (QA) frameworks. Each lot of our CJC-1295 with DAC peptide is verified for sequence fidelity and purity, ensuring that in vitro assays and animal models are free from confounding variable factors introduced by synthesis impurities or residual solvents.
Molecular Structure and the Bioconjugation Mechanism of DAC
Understanding the biochemistry of CJC-1295 with DAC requires examining both its primary amino acid sequence and the reactive functional group attached to its C-terminus. The core peptide consists of a modified GHRH(1-29) backbone containing four specific amino acid substitutions: D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27. These substitutions provide initial resistance to endopeptidase degradation while preserving affinity for the GHRH receptor.
The critical differentiator of this compound is the Drug Affinity Complex (DAC) reactive bioconjugative moiety—specifically, a maleimido-propionic acid (MPA) linker bound to the lysine residue at position 30 via a linker molecule. Upon exposure to serum or blood components in vivo or ex vivo, the maleimide group reacts rapidly and selectively with the free sulfhydryl group on Cys34 of circulating albumin. This covalent bonding creates a stable peptide-albumin conjugate.
Because endogenous serum albumin possesses a circulatory half-life measured in days rather than minutes, the conjugated peptide evades hepatic clearance and renal filtration. In preclinical models, this mechanism allows the GHRH domain to continuously interact with pituitary GHRH receptors, stimulating sustained growth hormone release without requiring frequent administration intervals. Research into growth hormone-releasing hormone (GHRH) analogs continues to focus heavily on these pharmacokinetic extended-release platforms.
Preclinical Pharmacokinetics and Sustained Secretory Dynamics
In animal literature, the pharmacokinetic profile of CJC-1295 with DAC contrasts sharply with non-conjugated secretagogues. Preclinical studies in rodent and non-human primate models demonstrate that a single administration yields measurable plasma concentrations of the active conjugate for up to 6 to 8 days, maintaining elevated baseline GH and IGF-1 levels over an extended duration.
Importantly, research shows that despite the continuous presence of the conjugated analog, pituitary somatotrophs retain their capacity for pulsatile secretion. The peptide amplifies endogenous baseline release rather than completely ablating the natural physiological rhythm of growth hormone synthesis. This characteristic makes CJC-1295 with DAC a preferred candidate for investigating long-term tissue remodeling, collagen synthesis, and protein accretion pathways in animal models.
Researchers exploring the broader spectrum of somatotropic regulation frequently compare this sustained elevation model against pulse-generating compounds found within our catalog of research peptides. Data gathered from these studies provide key insights into how sustained versus pulsatile GH elevations impact systemic physiological parameters.
Comparative Analysis: CJC-1295 With DAC vs. Related GHRH Analogs
When designing preclinical experiments, investigators must select the precise GHRH analog that matches their pharmacokinetic requirements. The primary distinction among compounds in this class centers on half-life, receptor residency time, and conjugation chemistry. Below is a comparative overview of key GHRH analogs evaluated in metabolic and somatotrophic research.
For studies requiring rapid, transient spikes in growth hormone secretion, compounds such as CJC-1295 No DAC (also designated as Modified GRF 1-29) or Sermorelin are typically selected due to their half-life of 30 minutes or less. Conversely, when researchers aim to sustain physiological IGF-1 output over several days without frequent dosing, CJC-1295 with DAC is the primary tool. Other specialized secretagogues like Tesamorelin offer targeted receptor binding profiles but lack the albumin-conjugating MPA linker that defines the DAC technology.
Furthermore, researchers often investigate synergistic signaling dynamics by pairing GHRH analogs with selective growth hormone secretagogue receptor (GHSR) agonists such as Ipamorelin. Combining a GHRH pathway activator with a ghrelin receptor agonist allows investigators to observe dual-receptor signaling amplification in in vitro pituitary cultures.
Analytical Quality Verification: HPLC, Mass Spectrometry, and COA Standards
In analytical peptide chemistry, physical appearance alone is insufficient to guarantee product quality. Low-grade peptides may contain deletion sequences, truncated fragments, unreacted maleimide moieties, or heavy metal residues from liquid-phase or solid-phase peptide synthesis (SPPS). PX1 Research implements rigorous, lot-specific analytical verification protocols to eliminate these variables.
Every batch of CJC-1295 with DAC undergoes High-Performance Liquid Chromatography (HPLC) to establish purity levels exceeding 98%. Replicated chromatograms must demonstrate a single sharp peak with minimal baseline drift or side-product interference. Additionally, Liquid Chromatography-Mass Spectrometry (LC-MS) is performed to confirm the exact molecular weight (typically ~3647.2 Da for the unreacted conjugate) and verify sequence fidelity.
All analytical data are compiled into a lot-specific Certificate of Analysis (COA) produced by an independent, ISO 17025 accredited laboratory. Facilities establishing wholesale laboratory accounts receive full access to these documents prior to batch dispatch, ensuring total transparency and compliance with institutional quality standards.
Endotoxin Testing and Bioburden Control in Peptide Synthesis
Endotoxins—lipopolysaccharides (LPS) derived from the outer membrane of Gram-negative bacteria—pose a significant threat to cell culture assays and animal studies. Exposure to elevated endotoxin levels can trigger unspecific inflammatory cascades, cytokine release, or cell toxicity, skewing metabolic and physiological data.
At PX1 Research, synthesized peptides undergo comprehensive purification and filtration steps designed to remove pyrogens. Final lyophilized vials are evaluated using standardized Limulus Amebocyte Lysate (LAL) chromogenic assays to confirm that endotoxin content remains strictly below established research limits (<0.01 EU/μg).
By enforcing strict bioburden controls and utilizing sterile, cGMP-compliant manufacturing environments, we deliver research compounds that produce reliable, uncontaminated data across cell culture and animal tissue models. Learn more about our analytical standards in our peptide research resource hub.
Laboratory Reconstitution and Solution Preparation Protocols
Lyophilized peptides must be reconstituted with precision to preserve their secondary structure and prevent premature degradation of the reactive DAC linker. Investigators should handle all lyophilized cakes within a certified laminar flow hood using aseptic techniques.
For standard laboratory applications, reconstitute CJC-1295 with DAC using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile normal saline, depending on the requirements of your assay system. Slowly inject the solvent down the inner glass wall of the vial rather than directing the liquid stream directly onto the lyophilized plug.
Gently swirl the vial in a circular motion until the cake is fully dissolved. Avoid vigorous agitation, shaking, or vortexing, as mechanical shear forces can cause peptide aggregation or denaturation of delicate peptide chains. Ensure the solution achieves complete optical clarity prior to volumetric pipetting.
Storage and Stability Specifications for Reconstituted Vials
Proper temperature control is essential for maintaining peptide bioactivity over extended experimental timelines. Unreconstituted lyophilized vials of CJC-1295 with DAC should be stored in a freezer at -20°C or -80°C, protected from light and moisture desiccation, where they remain stable for up to 24 months.
Once reconstituted, store liquid solutions under refrigeration at 2°C to 8°C. Because the maleimide functional group in the DAC moiety can undergo gradual hydrolysis over time in aqueous environments, reconstituted solutions should ideally be utilized within 14 to 28 days to ensure maximum reactivity during bioconjugation assays.
Avoid repeated freeze-thaw cycles, as thermal fluctuations promote mechanical stress and molecular breakdown. For long-term study protocols requiring aliquots, prepare single-use sub-aliquots in sterile polypropylene tubes immediately after initial reconstitution and freeze at -80°C.
PX1 Research Supply Chain, Manufacturing, and Shipping Standards
PX1 Research operates as a trusted USA-based supplier dedicated exclusively to institutional, academic, and private research entities. All peptides in our catalog are synthesized inside state-of-the-art domestic facilities following rigorous quality management protocols.
To prevent thermal degradation during transit, orders are fulfilled directly from our temperature-controlled distribution centers located in California and Arizona. We offer same-day shipping Monday through Friday for orders placed before standard cutoff times, utilizing insulated packaging designed to maintain product integrity.
When purchasing compounds within the growth hormone secretagogues category, research facilities can rely on PX1 Research for batch consistency, fully traceable chain-of-custody documentation, and uncompromising analytical standards.
Frequently Asked Questions
What is CJC-1295 with DAC?
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic 30-amino acid tetrasubstituted analog of growth hormone-releasing hormone (GHRH). It features a maleimido-propionic acid linker that covalently binds to circulating serum albumin, significantly extending its biological half-life in preclinical research models.
How does the DAC moiety alter the half-life of CJC-1295?
The Drug Affinity Complex (DAC) contains a reactive maleimide group that binds specifically to the Cys34 residue of albumin upon exposure to plasma. This covalent bond shields the peptide from rapid renal filtration and enzymatic cleavage by DPP-IV, extending its terminal half-life from minutes to up to 6–8 days in animal models.
What purity standard is guaranteed for CJC-1295 with DAC from PX1 Research?
Every lot of CJC-1295 with DAC supplied by PX1 Research is verified by high-performance liquid chromatography (HPLC) and mass spectrometry (MS) to exceed >98% chemical purity. Lot-specific Certificates of Analysis (COAs) are available for all batches.
What solvent should be used to reconstitute CJC-1295 with DAC for lab use?
Lyophilized CJC-1295 with DAC is typically reconstituted using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile normal saline, depending on the target protocol. Reconstitution should be conducted under aseptic conditions in a laminar flow hood.
How should reconstituted CJC-1295 with DAC be stored?
Reconstituted peptide solutions should be kept refrigerated at 2°C to 8°C and protected from light. To minimize hydrolysis of the maleimide group, liquid solutions should ideally be utilized within 14 to 28 days.
What is the key difference between CJC-1295 with DAC and CJC-1295 without DAC?
CJC-1295 with DAC includes a maleimido-propionic acid bioconjugate linker that binds serum albumin, extending its biological half-life to several days. CJC-1295 without DAC (Modified GRF 1-29) lacks this linker and exhibits a short half-life of approximately 30 minutes, producing rapid, transient GH release.
Does PX1 Research conduct endotoxin testing on peptide lots?
Yes. All batches undergo Limulus Amebocyte Lysate (LAL) endotoxin testing at independent ISO 17025 accredited testing facilities to confirm endotoxin levels are below strictly defined research thresholds (<0.01 EU/μg).
Where are PX1 Research peptides manufactured and dispatched from?
PX1 Research peptides are manufactured in US-based GMP-compliant facilities and shipped directly from dual distribution hubs in California and Arizona, with same-day dispatch available Monday through Friday.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.